Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.

TE Klein, RB Altman, Niclas Eriksson, BF Gage, SE Kimmel, MT Lee, NA Limdi, D Page, DM Roden, MJ Wagner, MD Caldwell, JA Johnson, YT Chen, MS Wen, Y Caraco, I Achache, S Blotnick, M Muszkat, JG Shin, HS Kim, G Suarez-Kurtz, JA Perini, E Silva-Assuncao, JL Anderson, BD Horne, JF Carlquist, RL Berg, JK Burmester, BC Goh, SC Lee, F Kamali, E Sconce, AK Daly, AH Wu, TY Langaee, H Feng, L Cavallari, K Momary, M Pirmohamed, A Jorgensen, CH Toh, P Williamson, H McLeod, JP Evans, KE Weck, C Brensinger, Y Nakamura, T Mushiroda, D Veenstra, L Meckley, MJ Rieder, AE Rettie, M Wadelius, H Melhus, CM Stein, U Schwartz, D Kurnik, E Deych, P Lenzini, C Eby, LY Chen, P Deloukas, A Motsinger-Reif, H Sagreiya, BS Srinivasan, E Lantz, T Chang, M Ritchie, LS Lu, Estimation of the warfarin dose with clinical and pharmacogenetic data The New England Journal of Medicine. ,vol. 360, pp. 753- 764 ,(2009) , 10.1056/NEJMOA0809329

Samar Ismail Hamdy, Masahiro Hiratsuka, Kaori Narahara, Mervat El-Enany, Nadia Moursi, Mohammed Salah-Eldin Ahmed, Michinao Mizugaki, Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. British Journal of Clinical Pharmacology. ,vol. 53, pp. 596- 603 ,(2002) , 10.1046/J.1365-2125.2002.01604.X

Michael D. Caldwell, Tarif Awad, Julie A. Johnson, Brian F. Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y. Langaee, Charles Eby, Cristi R. King, Amy Brower, John R. Schmelzer, Ingrid Glurich, Humberto J. Vidaillet, Steven H. Yale, Kai Qi Zhang, Richard L. Berg, James K. Burmester, CYP4F2 genetic variant alters required warfarin dose. Blood. ,vol. 111, pp. 4106- 4112 ,(2008) , 10.1182/BLOOD-2007-11-122010

J A Perini, C J Struchiner, E Silva-Assunção, G Suarez-Kurtz, Impact of CYP4F2 rs2108622 on the Stable Warfarin Dose in an Admixed Patient Cohort Clinical Pharmacology & Therapeutics. ,vol. 87, pp. 417- 420 ,(2010) , 10.1038/CLPT.2009.307

S E Kimmel, J Christie, C Kealey, Z Chen, M Price, C F Thorn, C M Brensinger, C W Newcomb, A S Whitehead, Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics Journal. ,vol. 8, pp. 53- 60 ,(2008) , 10.1038/SJ.TPJ.6500445

Gloria R. Grice, William E. Dager, Michael P. Gulseth, Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. American Journal of Health-system Pharmacy. ,vol. 66, pp. 123- 133 ,(2009) , 10.2146/AJHP080127

Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren, Lennart Holm, Jonatan Lindh, Anders Rane, Mia Wadelius, Panos Deloukas, A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose PLOS Genetics. ,vol. 5, pp. 1000433- ,(2009) , 10.1371/JOURNAL.PGEN.1000433

Jan van der Weide, Linda S. W. Steijns, Marga J. M. van Weelden, Keimpe de Haan, The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics. ,vol. 11, pp. 287- 291 ,(2001) , 10.1097/00008571-200106000-00002

Christina L. Aquilante, Maximilian T. Lobmeyer, Taimour Y. Langaee, Julie A. Johnson, Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy. ,vol. 24, pp. 720- 726 ,(2004) , 10.1592/PHCO.24.8.720.36074

H Schelleman, J Chen, Z Chen, J Christie, CW Newcomb, CM Brensinger, M Price, AS Whitehead, C Kealey, CF Thorn, FF Samaha, SE Kimmel, Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans Clinical Pharmacology & Therapeutics. ,vol. 84, pp. 332- 339 ,(2008) , 10.1038/CLPT.2008.101